Developer docs
API playgroundTry for free, no card

Search company profiles

WEP Clinical

Full company profile

uuid0008baf

Namestring
WEP Clinical
Legal namestring
WEP Clinical
Websiteurl
wepclinical.com
Company typeenum
Private
Founded yearint
2008
Descriptiontext

WEP Clinical is a privately held specialist Contract Research Organization (CRO) that delivers Phase I-IV clinical trial management, Expanded Access Programs (EAPs), Post-Trial Access Programs, Named Patient Programs, mobile clinical nursing, and global pharmaceutical distribution to biotech and pharmaceutical sponsors. Founded in 2008 as WE Pharma and rebranded to WEP Clinical in 2016 to reflect its 'With Every Patient' mission, the company positions itself as built for biotech sponsors with limited resources, distinguishing itself from large CROs through bespoke, flexible service configurations and end-to-end program management. Operations span 122 countries supported by four offices (London UK headquarters, Morrisville NC US headquarters, Dublin Ireland, and Breda Netherlands following the January 2026 acquisition of Siron Clinical).

The product portfolio is organized into three integrated divisions: WEP CRO Services covering trial planning and preparation, study startup, patient recruitment and retention, clinical support, biometrics, and study closeout; WEP Access Programs covering EAPs, Post-Trial Access Programs, Post-Approval Named Patient Programs (PA-NPPs), and third-party logistics; and Clinical Trial Nursing covering the WEP Flying Nurse Model and global operating model for decentralized home-based trial participation. Underlying technology includes IRT systems integration for randomization and drug supply management, patient feasibility and site selection analytics leveraging real-world data and epidemiological databases, and a licensed distribution infrastructure spanning Wholesale Distribution Authorizations, DEA and UK Home Office controlled substance licenses, and a UK Manufacturers 'Specials' License for secondary packaging.

Revenue is generated through bespoke, project-based service contracts with biotech and pharma sponsors, structured as multi-year engagements ranging from single-service needs to full end-to-end program management. Distribution of services is direct enterprise sales, while physical pharmaceutical distribution runs through approved specialist couriers for time- and temperature-sensitive shipments. The Jordan Company made an undisclosed private equity investment in November 2021 to support growth strategy. Leadership transitioned in November 2024 with co-founder Jaswinder Khera assuming sole company-wide CEO responsibilities after Jaswant Khera stepped away from day-to-day operations. The company has executed two strategic acquisitions: Wren Healthcare in 2020 (clinical nursing) and Siron Clinical in January 2026 (European CRO delivery), and announced a new London office at Chiswick Business Park in July 2026.

Short descriptiontext

WEP Clinical is a privately held specialist CRO providing Phase I-IV clinical trial management, Expanded Access and Named Patient Programs, mobile clinical nursing, and global pharmaceutical distribution across 122 countries to biotech and pharmaceutical sponsors.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical trial services, contract research organization, expanded access programs, named patient programs, mobile clinical nursing
Industry4 codes
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAI
Patient Recruitment, Site Feasibility & Trial Enablement CROs
SECONDARYHLAGAKAI
Clinical Quality Assurance (GCP QA, TMF/QMS oversight)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
SECONDARYHLAGAAAH
Pharmacovigilance, Risk Management & Medical Affairs CROs
NAICS code1 code
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Contract Research Organization (CRO) Services
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1CRO Clinical Trial Services
TypeManaged Services
Description

Full-service CRO offerings including Phase I–IV trial planning, execution, monitoring, data management, biometrics, regulatory affairs, and study closeout. Revenue generated through project-based service contracts with biotech and pharmaceutical sponsors, structured as bespoke solutions tailored to each client's exact requirements.

wepclinical.com
2Expanded Access Programs (EAPs) & Post-Trial Access
TypeProfessional Services
Description

Design and delivery of Expanded Access Programs and Post-Approval Named Patient Programs (PA-NPPs). WEP manages the end-to-end regulatory, logistics, and distribution process to supply unlicensed medicines to patients globally, returning positive ROI to sponsors.

wepclinical.com
3Mobile Clinical Nursing Solutions
TypeProfessional Services
Description

Clinical home nursing services enabling patients to participate in trials from their homes. Includes country coordinator teams and in-house nursing staff acquired through Wren Healthcare acquisition in 2020.

wepclinical.com
4Global Drug Distribution & Supply Chain
TypeTransaction Fee
Description

Global distribution of pharmaceutical products through licensed wholesale and manufacturing channels, managing time- and temperature-sensitive shipments via approved specialist couriers. Covers 122 countries with in-house language capabilities.

wepclinical.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain
Pricing details1 tier
1Flexible bespoke service model — single-service or full-service program management
ModelOtherBilling cadenceMulti-year contract
Notes

WEP creates flexible, tailored solutions to meet the exact level of support required for each client. They can provide single-service solutions for immediate needs or end-to-end management of drug development programs. Pricing is negotiated on a project-by-project basis.

wepclinical.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

WEP Clinical operates as a specialist Contract Research Organization (CRO) providing full-service Phase I–IV clinical trial management, Expanded Access Programs (EAPs), Post-Trial Access Programs, Post-Approval Named Patient Programs (PA-NPPs), mobile clinical nursing solutions for decentralized trials, and global pharmaceutical product distribution. The company supports 60+ clinical programmes and delivers investigational and licensed medicines across 122 countries, operating under WDA, Home Office/DEA, and UK Manufacturers 'Specials' licenses. Services span planning, regulatory affairs, biometrics, study closeout, and patient concierge support.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 210+ clinical programs delivered, 12,500+ patients served, 500+ sites managed
+2 more records
Product overview1 text field

WEP Clinical operates as a Complete CRO providing Drug Development, Treatment Access, and Commercialization Solutions through three integrated divisions: WEP CRO Services (Phase I-IV clinical trial management), WEP Access Programs (Expanded Access Programs, Post-Trial Access, Named Patient Programs), and Clinical Trial Nursing (mobile nursing solutions). The company supports 60+ clinical programs and delivers treatments across 122 countries, offering comprehensive services from planning through study closeout, including regulatory affairs, biometrics, pharmacovigilance, and specialized home nursing for decentralized trials.

Product and service3 records
1WEP CRO Services
CategoryCRO clinical trial management
Description

Full-service Phase I–IV clinical trial management for biotech and pharma sponsors, including planning, trial initiation, patient recruitment, execution monitoring, data management, biometrics, and study closeout.

2WEP Access Programs
CategoryExpanded Access and Named Patient Programs
Description

End-to-end Expanded Access Programs (EAPs) and Post-Trial Access solutions including Post-Approval Named Patient Programs (PA-NPP), Market Access Solutions, and 3PL services, supplying unlicensed or locally unavailable medicines to patients globally.

3Clinical Trial Nursing
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership17 partners
Strategic tierMinorTypeOthersAnnounced on2026-06-23
Description

WEP Clinical joined the Oliver Patch Project to champion children facing serious illness through National Patch Day. This is a patient advocacy/community engagement partnership supporting pediatric patients and their families.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-05
Description

WEP Clinical acquired Netherlands-based CRO Siron Clinical in January 2026. The acquisition expands WEP's global Phase I–IV trial delivery capabilities, adding European operational infrastructure in the Netherlands. This represents a significant strategic expansion of WEP's CRO service offerings.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-12-01
Description

Partnership with PlusUltra Pharma to supply HYFTOR® (sirolimus) gel to patients in EU/EEA countries (with the exception of Germany) through a named patient distribution program.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-07-17
Description

Partnership with Geron Corporation for an Expanded Access Protocol for imetelstat, a novel telomerase inhibitor. WEP manages the EAP to provide access to the investigational drug for patients outside of the clinical trial setting.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-07-13
Description

Partnership with Theratechnologies to launch a Named Patient Program for EGRIFTA SV® (tesamorelin), providing access to the treatment for patients in specified regions.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-06-20
Description

Partnership with Pharming Group to supply leniolisib post-FDA approval through a Post-Approval Named Patient Program. Previously partnered on an EAP for leniolisib in 2022.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-03-20
Description

Partnership with Solasia Pharma K.K. to launch DARVIAS Named Patient Program for access to this oncology product.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-02-16
Description

Partnership to provide DANYELZA® (naxitamab) through a Named Patient Access Program in Europe for pediatric neuroblastoma patients.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-02-06
Description

Partnership with Taimed Biologics to launch a TROGARZO® (ibalizumab-uiyk) Named Patient Program, providing access to this HIV treatment for patients in ex-US countries.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2022-08-17
Description

Partnership with Kiniksa to launch ARCALYST® (rilonacept) Named Patient Program, providing access for patients with autoinflammatory conditions.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-05-04
Description

Partnership with Sellas Life Sciences Group to launch an Expanded Access Program for galinpepimut-S, a WT1-targeted immunotherapeutic.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-07-19
Description

Master Services Agreement with Medlab to bring NANABIS™ and NANOCBD™ to patients in the UK and Europe via ethical named patient programmes.

13Nabriva Therapeutics
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2021-03-25
Description

Partnership with Nabriva Therapeutics expanded the availability of XENLETA® (lefamulin) Named Patient Program globally.

wepclinical.com
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2020-07-01
Description

Partnership with BTG Specialty Pharmaceuticals for European supply of VORAXAZE® (prothrombin complex concentrate). Extended in 2021 to gain worldwide (ex-US) distribution rights for DIGIFAB® (digoxin immune fab).

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-06-25
Description

Acquisition of Wren Healthcare (specialist nursing and clinical education company founded by Antony Reynolds in 2018) in 2020. This acquisition brought in-house clinical nursing capabilities to WEP, forming the foundation of WEP's mobile nursing solutions.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2020-06-01
Description

Partnership with Mylan to provide product for highly drug-resistant tuberculosis, supporting global access to critical anti-infective treatments.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2020-01-23
Description

Partnership for Named Patient supply of VISTOGARD® (uridine triacetate) for the treatment of patients experiencing toxicity from fluorouracil or capecitabine overdose.

Recent move11 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

UK-headquartered specialty pharma services company with overlapping Expanded Access Program, Named Patient Program, and clinical trial supply capabilities — the closest direct competitor in the global access-program and unlicensed-medicines distribution space.

TypeDirect peer
Description

Specialty pharma services provider focused on compassionate use, expanded access, and clinical trial supply across multiple geographies — direct overlap with WEP's access programs and global drug distribution offerings.

TypeDirect peer
Description

Mid-sized global CRO with deep Phase I-IV trial expertise; WEP's CFO Karl Challender previously held senior roles there, evidencing comparable operating model and therapeutic coverage, especially in biotech-focused studies.

4Veristat
TypeDirect peer
Description

Specialty CRO focused on complex clinical trials for small and mid-sized biopharma; comparable to WEP in biotech-centric positioning, agile bespoke service model, and senior leadership pedigree (WEP COO Shaheen Limbada previously worked at Veristat).

TypeDirect peer
Description

Public CRO explicitly built around serving small and mid-sized biotech sponsors with full-service Phase I-IV trial delivery — the most direct publicly traded comp for WEP's 'built for biotech' positioning and operating model.

TypeBroad incumbent
Description

Largest global CRO and clinical research services provider; overlaps broadly with WEP's Phase I-IV, biometrics, and patient recruitment offerings but at materially larger scale and with broader pharma focus.

TypeBroad incumbent
Description

Global CRO formed through PRA Health Sciences merger, providing full-service clinical development across all phases; competes for the same biotech sponsor wallet with broader therapeutic and geographic coverage than WEP.

TypeBroad incumbent
Description

Owns PPD, a top global CRO; WEP's EVP Commercial Lee Sutton spent 7 years in Thermo Fisher global commercial leadership, evidencing deep familiarity with PPD's go-to-market as a competitor across CRO and access services.

TypeBroad incumbent
Description

Large CRO with biotech and biopharma focus spanning clinical development and commercialization; overlapping client base and service scope with WEP but at significantly greater scale.

TypeBroad incumbent
Description

Diversified diagnostics and drug development company whose Covance segment offers global CRO services spanning Phase I-IV — broad incumbent competing with WEP for biotech clinical trial and central lab business.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

WEP Clinical

Contract Research Organization (CRO) Serviceswepclinical.com

WEP Clinical is a privately held specialist CRO providing Phase I-IV clinical trial management, Expanded Access and Named Patient Programs, mobile clinical nursing, and global pharmaceutical distribution across 122 countries to biotech and pharmaceutical sponsors.

What WEP Clinical does

WEP Clinical is a privately held specialist Contract Research Organization (CRO) that delivers Phase I-IV clinical trial management, Expanded Access Programs (EAPs), Post-Trial Access Programs, Named Patient Programs, mobile clinical nursing, and global pharmaceutical distribution to biotech and pharmaceutical sponsors. Founded in 2008 as WE Pharma and rebranded to WEP Clinical in 2016 to reflect its 'With Every Patient' mission, the company positions itself as built for biotech sponsors with limited resources, distinguishing itself from large CROs through bespoke, flexible service configurations and end-to-end program management. Operations span 122 countries supported by four offices (London UK headquarters, Morrisville NC US headquarters, Dublin Ireland, and Breda Netherlands following the January 2026 acquisition of Siron Clinical).

The product portfolio is organized into three integrated divisions: WEP CRO Services covering trial planning and preparation, study startup, patient recruitment and retention, clinical support, biometrics, and study closeout; WEP Access Programs covering EAPs, Post-Trial Access Programs, Post-Approval Named Patient Programs (PA-NPPs), and third-party logistics; and Clinical Trial Nursing covering the WEP Flying Nurse Model and global operating model for decentralized home-based trial participation. Underlying technology includes IRT systems integration for randomization and drug supply management, patient feasibility and site selection analytics leveraging real-world data and epidemiological databases, and a licensed distribution infrastructure spanning Wholesale Distribution Authorizations, DEA and UK Home Office controlled substance licenses, and a UK Manufacturers 'Specials' License for secondary packaging.

Revenue is generated through bespoke, project-based service contracts with biotech and pharma sponsors, structured as multi-year engagements ranging from single-service needs to full end-to-end program management. Distribution of services is direct enterprise sales, while physical pharmaceutical distribution runs through approved specialist couriers for time- and temperature-sensitive shipments. The Jordan Company made an undisclosed private equity investment in November 2021 to support growth strategy. Leadership transitioned in November 2024 with co-founder Jaswinder Khera assuming sole company-wide CEO responsibilities after Jaswant Khera stepped away from day-to-day operations. The company has executed two strategic acquisitions: Wren Healthcare in 2020 (clinical nursing) and Siron Clinical in January 2026 (European CRO delivery), and announced a new London office at Chiswick Business Park in July 2026.

WEP Clinical firmographics

Firmographics
Name
WEP Clinical
Legal name
WEP Clinical
Website
https://wepclinical.com
Company type
Private
Founded year
2008
Operating status
Operating
Headcount range
251–500 employees
Short description
WEP Clinical is a privately held specialist CRO providing Phase I-IV clinical trial management, Expanded Access and Named Patient Programs, mobile clinical nursing, and global pharmaceutical distribution across 122 countries to biotech and pharmaceutical sponsors.
Ownership category
akta.pro rank

WEP Clinical industry classification

Industry
Product category
Contract Research Organization (CRO) Services
NAICS
Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAI
Patient Recruitment, Site Feasibility & Trial Enablement CROs
SECONDARYHLAGAKAI
Clinical Quality Assurance (GCP QA, TMF/QMS oversight)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
SECONDARYHLAGAAAH
Pharmacovigilance, Risk Management & Medical Affairs CROs

Keywords

  • Clinical trial services
  • Contract research organization
  • Expanded access programs
  • Named patient programs
  • Mobile clinical nursing

Where WEP Clinical is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices4 records

Markets served

WEP Clinical business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain

Revenue model

  1. CRO Clinical Trial Services: Full-service CRO offerings including Phase I–IV trial planning, execution, monitoring, data management, biometrics, regulatory affairs, and study closeout. Revenue generated through project-based service contracts with biotech and pharmaceutical sponsors, structured as bespoke solutions tailored to each client's exact requirements.
  2. Expanded Access Programs (EAPs) & Post-Trial Access: Design and delivery of Expanded Access Programs and Post-Approval Named Patient Programs (PA-NPPs). WEP manages the end-to-end regulatory, logistics, and distribution process to supply unlicensed medicines to patients globally, returning positive ROI to sponsors.
  3. Mobile Clinical Nursing Solutions: Clinical home nursing services enabling patients to participate in trials from their homes. Includes country coordinator teams and in-house nursing staff acquired through Wren Healthcare acquisition in 2020.
  4. Global Drug Distribution & Supply Chain: Global distribution of pharmaceutical products through licensed wholesale and manufacturing channels, managing time- and temperature-sensitive shipments via approved specialist couriers. Covers 122 countries with in-house language capabilities.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractFlexible bespoke service model — single-service or full-service program management

Go-to-market motion2 records

Distribution channels2 records

Marketing channels9 records

WEP Clinical product offering

Product offering

Core offering

WEP Clinical operates as a specialist Contract Research Organization (CRO) providing full-service Phase I–IV clinical trial management, Expanded Access Programs (EAPs), Post-Trial Access Programs, Post-Approval Named Patient Programs (PA-NPPs), mobile clinical nursing solutions for decentralized trials, and global pharmaceutical product distribution. The company supports 60+ clinical programmes and delivers investigational and licensed medicines across 122 countries, operating under WDA, Home Office/DEA, and UK Manufacturers 'Specials' licenses. Services span planning, regulatory affairs, biometrics, study closeout, and patient concierge support.

Product overview

WEP Clinical operates as a Complete CRO providing Drug Development, Treatment Access, and Commercialization Solutions through three integrated divisions: WEP CRO Services (Phase I-IV clinical trial management), WEP Access Programs (Expanded Access Programs, Post-Trial Access, Named Patient Programs), and Clinical Trial Nursing (mobile nursing solutions). The company supports 60+ clinical programs and delivers treatments across 122 countries, offering comprehensive services from planning through study closeout, including regulatory affairs, biometrics, pharmacovigilance, and specialized home nursing for decentralized trials.

Differentiator

Problem solved

Functional benefit

Products and services

  • WEP CRO Services Full-service Phase I–IV clinical trial management for biotech and pharma sponsors, including planning, trial initiation, patient recruitment, execution monitoring, data management, biometrics, and study closeout.
  • WEP Access Programs End-to-end Expanded Access Programs (EAPs) and Post-Trial Access solutions including Post-Approval Named Patient Programs (PA-NPP), Market Access Solutions, and 3PL services, supplying unlicensed or locally unavailable medicines to patients globally.
  • Clinical Trial Nursing

Quantifiable outcome

  • 210+ clinical programs delivered, 12,500+ patients served, 500+ sites managed
  • +2 more outcomes

Companies that use WEP Clinical

Customer profile

Named customers8 records

Segments4 records

Ideal customer profiles3 records

WEP Clinical technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

WEP Clinical partnerships and signals

Strategic signal

Partnerships

17 partnerships are on record, tiered minor, core and major.

  • Oliver Patch ProjectminorOthers · 23 June 2026WEP Clinical joined the Oliver Patch Project to champion children facing serious illness through National Patch Day. This is a patient advocacy/community engagement partnership supporting pediatric patients and their families.
  • Siron ClinicalcoreStrategic or Co-development Partner · 5 January 2026WEP Clinical acquired Netherlands-based CRO Siron Clinical in January 2026. The acquisition expands WEP's global Phase I–IV trial delivery capabilities, adding European operational infrastructure in the Netherlands. This represents a significant strategic expansion of WEP's CRO service offerings.
  • PlusUltra PharmamajorStrategic or Co-development Partner · 1 December 2023Partnership with PlusUltra Pharma to supply HYFTOR® (sirolimus) gel to patients in EU/EEA countries (with the exception of Germany) through a named patient distribution program.
  • Geron CorporationmajorStrategic or Co-development Partner · 17 July 2023Partnership with Geron Corporation for an Expanded Access Protocol for imetelstat, a novel telomerase inhibitor. WEP manages the EAP to provide access to the investigational drug for patients outside of the clinical trial setting.
  • TheratechnologiesmajorStrategic or Co-development Partner · 13 July 2023Partnership with Theratechnologies to launch a Named Patient Program for EGRIFTA SV® (tesamorelin), providing access to the treatment for patients in specified regions.
  • Pharming GroupmajorStrategic or Co-development Partner · 20 June 2023Partnership with Pharming Group to supply leniolisib post-FDA approval through a Post-Approval Named Patient Program. Previously partnered on an EAP for leniolisib in 2022.
  • Solasia Pharma K.K.minorStrategic or Co-development Partner · 20 March 2023Partnership with Solasia Pharma K.K. to launch DARVIAS Named Patient Program for access to this oncology product.
  • Y-mAbs TherapeuticsmajorStrategic or Co-development Partner · 16 February 2023Partnership to provide DANYELZA® (naxitamab) through a Named Patient Access Program in Europe for pediatric neuroblastoma patients.
  • Taimed BiologicsmajorStrategic or Co-development Partner · 6 February 2023Partnership with Taimed Biologics to launch a TROGARZO® (ibalizumab-uiyk) Named Patient Program, providing access to this HIV treatment for patients in ex-US countries.
  • Kiniksa PharmaceuticalsmajorStrategic or Co-development Partner · 17 August 2022Partnership with Kiniksa to launch ARCALYST® (rilonacept) Named Patient Program, providing access for patients with autoinflammatory conditions.
  • Sellas Life Sciences GroupminorStrategic or Co-development Partner · 4 May 2022Partnership with Sellas Life Sciences Group to launch an Expanded Access Program for galinpepimut-S, a WT1-targeted immunotherapeutic.
  • MedlabminorStrategic or Co-development Partner · 19 July 2021Master Services Agreement with Medlab to bring NANABIS™ and NANOCBD™ to patients in the UK and Europe via ethical named patient programmes.
  • Nabriva TherapeuticsmajorStrategic or Co-development Partner · 25 March 2021Partnership with Nabriva Therapeutics expanded the availability of XENLETA® (lefamulin) Named Patient Program globally.
  • BTG Specialty PharmaceuticalsmajorStrategic or Co-development Partner · 1 July 2020Partnership with BTG Specialty Pharmaceuticals for European supply of VORAXAZE® (prothrombin complex concentrate). Extended in 2021 to gain worldwide (ex-US) distribution rights for DIGIFAB® (digoxin immune fab).
  • Wren HealthcarecoreStrategic or Co-development Partner · 25 June 2020Acquisition of Wren Healthcare (specialist nursing and clinical education company founded by Antony Reynolds in 2018) in 2020. This acquisition brought in-house clinical nursing capabilities to WEP, forming the foundation of WEP's mobile nursing solutions.
  • Mylan (now Viatris)majorStrategic or Co-development Partner · 1 June 2020Partnership with Mylan to provide product for highly drug-resistant tuberculosis, supporting global access to critical anti-infective treatments.
  • Wellstat Therapeutics CorporationmajorStrategic or Co-development Partner · 23 January 2020Partnership for Named Patient supply of VISTOGARD® (uridine triacetate) for the treatment of patients experiencing toxicity from fluorouracil or capecitabine overdose.

Scale indicators7 records

Recent moves11 records

Expansion highlights6 records

WEP Clinical competitors and assessment

Company assessment

Direct peers

  • Clinigen Group: UK-headquartered specialty pharma services company with overlapping Expanded Access Program, Named Patient Program, and clinical trial supply capabilities — the closest direct competitor in the global access-program and unlicensed-medicines distribution space.
  • Inceptua Group: Specialty pharma services provider focused on compassionate use, expanded access, and clinical trial supply across multiple geographies — direct overlap with WEP's access programs and global drug distribution offerings.
  • Worldwide Clinical Trials: Mid-sized global CRO with deep Phase I-IV trial expertise; WEP's CFO Karl Challender previously held senior roles there, evidencing comparable operating model and therapeutic coverage, especially in biotech-focused studies.
  • Veristat: Specialty CRO focused on complex clinical trials for small and mid-sized biopharma; comparable to WEP in biotech-centric positioning, agile bespoke service model, and senior leadership pedigree (WEP COO Shaheen Limbada previously worked at Veristat).
  • Medpace Holdings: Public CRO explicitly built around serving small and mid-sized biotech sponsors with full-service Phase I-IV trial delivery — the most direct publicly traded comp for WEP's 'built for biotech' positioning and operating model.

Broad incumbents

  • IQVIA: Largest global CRO and clinical research services provider; overlaps broadly with WEP's Phase I-IV, biometrics, and patient recruitment offerings but at materially larger scale and with broader pharma focus.
  • ICON plc: Global CRO formed through PRA Health Sciences merger, providing full-service clinical development across all phases; competes for the same biotech sponsor wallet with broader therapeutic and geographic coverage than WEP.
  • Thermo Fisher Scientific (PPD): Owns PPD, a top global CRO; WEP's EVP Commercial Lee Sutton spent 7 years in Thermo Fisher global commercial leadership, evidencing deep familiarity with PPD's go-to-market as a competitor across CRO and access services.
  • Syneos Health: Large CRO with biotech and biopharma focus spanning clinical development and commercialization; overlapping client base and service scope with WEP but at significantly greater scale.
  • Labcorp (Covance Clinical Development): Diversified diagnostics and drug development company whose Covance segment offers global CRO services spanning Phase I-IV — broad incumbent competing with WEP for biotech clinical trial and central lab business.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

WEP Clinical social profiles

Digital presence

WEP Clinical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

WEP Clinical leadership team

Management profile

Number of profiles

Profiles12 records

WEP Clinical subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

WEP Clinical funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

WEP Clinical M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about WEP Clinical

What does WEP Clinical do?

WEP Clinical operates as a specialist Contract Research Organization (CRO) providing full-service Phase I–IV clinical trial management, Expanded Access Programs (EAPs), Post-Trial Access Programs, Post-Approval Named Patient Programs (PA-NPPs), mobile clinical nursing solutions for decentralized trials, and global pharmaceutical product distribution. The company supports 60+ clinical programmes and delivers investigational and licensed medicines across 122 countries, operating under WDA, Home Office/DEA, and UK Manufacturers 'Specials' licenses. Services span planning, regulatory affairs, biometrics, study closeout, and patient concierge support.

Is WEP Clinical a public or private company?

WEP Clinical is a private company. It is classified as private equity controlled and is currently operating.

When was WEP Clinical founded?

WEP Clinical was founded in 2008. It employs 251 to 500 people.

Where is WEP Clinical based?

WEP Clinical is headquartered in London, United Kingdom, in the Europe region.

How does WEP Clinical make money?

Four revenue lines are on record. CRO Clinical Trial Services are the primary driver. The others are expanded Access Programs (EAPs) & Post-Trial Access, mobile Clinical Nursing Solutions and global Drug Distribution & Supply Chain.

Who are WEP Clinical's main competitors?

Direct peers on record are Clinigen Group, Inceptua Group, Worldwide Clinical Trials, Veristat and Medpace Holdings. Broad incumbents are IQVIA, ICON plc, Thermo Fisher Scientific (PPD), Syneos Health and Labcorp (Covance Clinical Development).

Does WEP Clinical have an API?

No public API is recorded for WEP Clinical.

What industry is WEP Clinical in?

WEP Clinical's product category is Contract Research Organization (CRO) Services. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGAAAI, Patient Recruitment, Site Feasibility & Trial Enablement CROs. Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageWEP Clinical Joins the Oliver Patch Project to Champion Children Facing Serious Illness Through National Patch DayWEP Clinical, a global clinical research organization, announced its sponsorship of National Patch Day through the Oliver Patch Project, a nonprofit supporting children facing serious illnesses. As one of this year's sponsors, WEP will fund the design and distribution of one of 30 brand-new patches, which will also be included in all WEP pediatric trials going forward. The Oliver Patch Project has delivered over 100,000 patches to children and teens across all 50 US states since its founding.Business Wire BlogWEP Clinical Joins the Oliver Patch Project to Champion Children Facing Serious Illness Through National Patch DayWEP Clinical announced its sponsorship of National Patch Day through the Oliver Patch Project, a nonprofit supporting pediatric patients. WEP will fund the design and distribution of one of 30 new patches, and the project has delivered over 100,000 patches since its founding. WEP will also include Oliver's patches in all its pediatric trials.AijournBuilt to Scale: CRO Growth with the Right eClinical Partner, Upcoming Webinar Hosted by XtalksXtalks is hosting a free webinar on June 29, 2026 focused on CRO growth strategies and the importance of integrated eClinical solutions, featuring speakers from WEP Clinical and Trial Interactive. The webinar will showcase how WEP Clinical leveraged Trial Interactive's platform to scale across its four core service areas while maintaining operational quality and sponsor responsiveness. Attendees are expected to gain insights into building operational infrastructure capable of supporting growth without sacrificing quality.ThemalaysianreserveBuilt to Scale: CRO Growth with the Right eClinical Partner, Upcoming Webinar Hosted by XtalksXtalks is hosting a free webinar on June 29, 2026, focused on how Contract Research Organizations can scale operations by leveraging integrated eClinical solutions from the outset, featuring WEP Clinical and Trial Interactive as case study participants. The webinar will showcase how WEP Clinical, a global CRO operating across 150+ countries, used Trial Interactive's platform to expand its portfolio across Clinical Trials, Expanded Access, Home Health, and Post-Approval Market Access services. Attendees will learn practical frameworks for converting operational efficiency into new business capacity and maintaining quality during growth.PR NewswireBuilt to Scale: CRO Growth with the Right eClinical Partner, Upcoming Webinar Hosted by XtalksXtalks is hosting a free webinar on June 29, 2026, featuring WEP Clinical and Trial Interactive discussing how integrated eClinical solutions enable CROs to scale operations and win business. The session will showcase WEP Clinical's experience leveraging Trial Interactive's platform across its four core service areas, emphasizing how operational efficiency translates into new business capacity. The webinar targets CRO professionals seeking to strengthen their competitive positioning and operational infrastructure.BioSpaceCytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast CancerCytoDyn announced the first patient dosed in its expanded access program for leronlimab in triple-negative breast cancer, providing access outside clinical studies. The program aims to generate real-world insights into CCR5 inhibition's effect on the tumor microenvironment, including PD-L1 expression, and is open for physician referrals.GlobeNewswireCytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast CancerCytoDyn announced that an anonymous benefactor has committed funding for an expanded access program for triple-negative breast cancer patients. The program, managed by Every Patient (WEP Clinical), is expected to open in March 2026 under FDA guidelines. It aims to provide access to leronlimab for patients who have exhausted approved treatments.InvestorsinhealthcareNetherlands: WEP Clinical expands global footprint with acquisition of Siron ClinicalUS-based WEP Clinical has acquired Netherlands-based Siron Clinical, a CRO services provider operating across Europe, Israel, and Turkey, expanding WEP's global footprint in clinical trial services. The acquisition combines WEP's global infrastructure with Siron's operational expertise in complex, rare, and specialized therapeutic areas, including orphan diseases, pediatric research, and medical device trials. Both companies state the combined entity will offer more robust and scalable solutions for biotech sponsors worldwide.Business Wire IndiaWEP Clinical Acquires Netherlands-Based CRO Siron Clinical, Expanding Global Phase I–IV Trial Delivery CapabilitiesWEP Clinical, a US-based full-service CRO, has acquired Siron Clinical, a Netherlands-based European CRO specializing in complex clinical operations for biotech companies. The acquisition, whose financial terms were not disclosed, expands WEP's global footprint and integrates Siron's expertise in orphan diseases, pediatric research, and medical device trials into WEP's existing clinical trials division. Siron will continue operating from its current locations in the Netherlands, Belgium, and Germany, with its team of clinical research professionals across Europe and the Middle East joining WEP.AETOSWireWEP Clinical Acquires Netherlands-Based CRO Siron Clinical, Expanding Global Phase I–IV Trial Delivery CapabilitiesWEP Clinical acquired Siron Clinical, a Netherlands-based CRO, to expand its global Phase I-IV trial delivery capabilities. Siron, founded in 2000, has supported over 120 studies and will integrate into WEP's Clinical Trials division. The deal aims to offer sponsors seamless support from early-phase development through post-approval research.